SCHEMBL6469006

SCHEMBL6469006

CC(O)c1ccc(C(N)=O)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.47
SIRT6 Q8N6T7 2/20 0.41
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NNMT P40261 1/20 0.38
PLG P00747 1/20 0.38
PLAU P00749 1/20 0.38
ADORA3 P0DMS8 1/20 0.37
TSHR P16473 1/20 0.37
MC4R P32245 1/20 0.37
ADRA1A P35348 1/20 0.37
MC3R P41968 1/20 0.37
HRH3 Q9Y5N1 2/20 0.36
P4HTM Q9NXG6 1/20 0.36
TLR8 Q9NR97 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
APP P05067 1/20 0.36
LCK P06239 1/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8953636 0.87 KMT2A (0.49) KMT2ASIRT6NNMTADORA3TSHR
SCHEMBL6650658 0.86 KMT2A (0.45) KMT2ASIRT6NNMTADORA3TSHR
SCHEMBL27837540 0.83 P4HTM (0.52) KMT2ATSHRP4HTMLMNAMAPT
SCHEMBL6469092 0.82 KMT2A (0.41) KMT2ASIRT6NNMTADORA3TSHR
SCHEMBL2677914 0.81 ALDH1A1 (0.44) KMT2ASIRT6TSHRP4HTMNPC1
SCHEMBL22888217 0.80 KMT2A (0.54) KMT2ASIRT6NNMTADORA3TSHR
SCHEMBL16465368 0.79 KMT2A (0.53) KMT2ASIRT6NNMTADORA3TSHR
SCHEMBL29144076 0.79 SIRT6 (0.46) KMT2ASIRT6NNMTADORA3TSHR
SCHEMBL30242017 0.79 SIRT6 (0.46) KMT2ASIRT6NNMTADORA3TSHR
SCHEMBL31036563 0.79 MAPK1 (0.59) KMT2AHRH3LCKNPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders APP, BACE1, SNCA KMT2A 2085/4885SIRT6 750/4885NOS3 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.